Page 2 - சூலா தடுப்பூசி ஆராய்ச்சி மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
nikkei.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nikkei.com Daily Mail and Mail on Sunday newspapers.
Latest news: Anutin (second from left) holding a news conference to give an update on the progress of the ‘ChulaCov19’ vaccine in Bangkok. Reuters
The country’s second domestically developed vaccine will soon undergo human trials, officials said, adding that the plan was to produce up to five million doses by the end of the year.
The vaccine, developed by Thailand’s Chulalongkorn University, had success in trials in mice and monkeys and is due to be tested on humans in late April or early May, Kiat Ruxrungtham of the Chula Vaccine Research Center said.
“By year-end we should have a production capacity of one to five million doses annually, ” Kiat told a news conference yesterday, adding this could later rise to about 20 million doses per year.
42 Researchers from the Chula Vaccine Research Centre of Chulalongkorn University s Faculty of Medicine host a press briefing on the progress of the country s first-ever mRNA ChulaCOV 19 vaccine at Chulalongkorn Hospital. (Photo by Somchai Poomlard)
The mRNA ChulaCOV 19 vaccine which Thailand is developing will enter the first stage of human trials in May with hopes to produce a maximum of five million shots with its partner, vaccine manufacturer BioNet Asia, by the end of this year.
It will be followed by the beginning of a cocktail vaccine development, which will be the second vaccine generation to fight the mutated SARS-CoV-2 virus strains in the next two months.
Thailand's second domestically developed vaccine will soon undergo human trials, officials said on Thursday, adding that the plan was to produce up to five million doses by the end of the year.